Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial.

Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial.

INTRODUCTION:Recent findings from onchocerciasis-endemic foci uphold that increasing ivermectin coverage reduces the epilepsy incidence, and anecdotal evidence suggests seizure frequency reduction in persons with onchocerciasis-associated epilepsy, when treated with ivermectin. We conducted a random...

Full description

Bibliographic Details
Main Authors:	Michel Mandro, Joseph Nelson Siewe Fodjo, Deby Mukendi, Alfred Dusabimana, Sonia Menon, Steven Haesendonckx, Richard Lokonda, Swabra Nakato, Francoise Nyisi, Germain Abhafule, Deogratias Wonya'Rossi, Jean Marie Jakwong, Patrick Suykerbuyk, Jacques Meganck, An Hotterbeekx, Robert Colebunders
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS Neglected Tropical Diseases
Online Access:	https://doi.org/10.1371/journal.pntd.0007966

Similar Items

Single versus Multiple Dose Ivermectin Regimen in Onchocerciasis-Infected Persons with Epilepsy Treated with Phenobarbital: A Randomized Clinical Trial in the Democratic Republic of Congo
by: Michel Mandro, et al.
Published: (2020-03-01)

Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density.
by: Joseph Nelson Siewe Fodjo, et al.
Published: (2019-07-01)

Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy: A randomized clinical trial
by: M. Mandro, et al.
Published: (2020-12-01)

Urinary N-acetyltyramine-O,β-glucuronide in Persons with Onchocerciasis<i>-</i>Associated Epilepsy
by: An Hotterbeekx, et al.
Published: (2020-03-01)

High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo
by: Evy Lenaerts, et al.
Published: (2018-08-01)

Serotonin Levels in the Serum of Persons with Onchocerciasis-Associated Epilepsy: A Case-Control Study
by: Melissa Krizia Vieri, et al.
Published: (2021-06-01)

Community perceptions of epilepsy and its treatment in an onchocerciasis endemic region in Ituri, Democratic Republic of Congo
by: Housseini Dolo, et al.
Published: (2018-12-01)

Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
by: Joseph Nelson Siewe Fodjo, et al.
Published: (2019-08-01)

Onchocerciasis-associated epilepsy an unrecognised important preventable public health problem
by: R. Colebunders, et al.
Published: (2020-12-01)

High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment
by: Deby Mukendi, et al.
Published: (2019-02-01)

Comparison of Diagnostic Tests for <i>Onchocerca volvulus</i> in the Democratic Republic of Congo
by: An Hotterbeekx, et al.
Published: (2020-06-01)

OV16 Seroprevalence among Persons with Epilepsy in Onchocerciasis Endemic Regions: A Multi-Country Study
by: Alfred Dusabimana, et al.
Published: (2020-10-01)

Ivermectin Treatment Response in Onchocerca Volvulus Infected Persons with Epilepsy: A Three-Country Short Cohort Study
by: Alfred Dusabimana, et al.
Published: (2020-07-01)

Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo
by: Melissa Krizia Vieri, et al.
Published: (2021-03-01)

The onchocerciasis hypothesis of nodding syndrome.
by: Robert Colebunders, et al.
Published: (2023-08-01)

Impact of 19 years of mass drug administration with ivermectin on epilepsy burden in a hyperendemic onchocerciasis area in Cameroon
by: Charlotte Boullé, et al.
Published: (2019-03-01)

Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature
by: Melissa Krizia Vieri, et al.
Published: (2021-03-01)

Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study
by: Michel Mandro, et al.
Published: (2018-10-01)

No Evidence for the Involvement of Leiomodin-1 Antibodies in the Pathogenesis of Onchocerciasis-Associated Epilepsy
by: An Hotterbeekx, et al.
Published: (2021-07-01)

Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with <i>Onchocerca volvulus</i>
by: Alfred Dusabimana, et al.
Published: (2020-12-01)

Onchocerciasis Prevalence among Persons with Epilepsy in an Onchocerciasis Hypo-Endemic Area in the Democratic Republic of Congo: A Cross-Sectional Study
by: An Hotterbeekx, et al.
Published: (2021-03-01)

From river blindness to river epilepsy: Implications for onchocerciasis elimination programmes.
by: Robert Colebunders, et al.
Published: (2019-07-01)

Safety of ivermectin during pregnancy
by: Stijn Van Hees, et al.
Published: (2020-03-01)

Reducing onchocerciasis-associated morbidity in onchocerciasis-endemic foci with high ongoing transmission: a focus on the children.
by: Robert Colebunders, et al.
Published: (2022-03-01)

Surveillance for Onchocerciasis-Associated Epilepsy and OV16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening
by: Alfred Dusabimana, et al.
Published: (2022-02-01)

Comprehensive management of epilepsy in onchocerciasis-endemic areas: lessons learnt from community-based surveys
by: Joseph Nelson Siewe Fodjo, et al.
Published: (2019-02-01)

Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions
by: Robert Colebunders, et al.
Published: (2019-10-01)

Correction: Dusabimana et al. Surveillance for Onchocerciasis-Associated Epilepsy and Ov16 IgG4 Testing of Children 6–10 Years Old Should Be Used to Identify Areas Where Onchocerciasis Elimination Programs Need Strengthening. <i>Pathogens</i> 2022, <i>11</i>, 281
by: Alfred Dusabimana, et al.
Published: (2022-06-01)

Onchocerciasis-associated epilepsy: another piece in the puzzle from the Mahenge mountains, southern Tanzania
by: Christoph Kaiser, et al.
Published: (2019-05-01)

Onchocerca volvulus is not detected in the cerebrospinal fluid of persons with onchocerciasis-associated epilepsy
by: An Hotterbeekx, et al.
Published: (2020-02-01)

Report of the first international workshop on onchocerciasis-associated epilepsy
by: Robert Colebunders, et al.
Published: (2018-03-01)

Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study
by: Kenneth Bentum Otabil, et al.
Published: (2023-11-01)

Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin
by: Joseph Nelson Siewe Fodjo, et al.
Published: (2018-12-01)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.
by: Nana O Wilson, et al.
Published: (2016-12-01)

Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin
by: Kenneth Bentum Otabil, et al.
Published: (2023-08-01)

Can ivermectin mass treatments eliminate onchocerciasis in Africa?
by: M. Winnen, et al.

Can ivermectin mass treatments eliminate onchocerciasis in Africa?
by: Winnen M., et al.
Published: (2002-01-01)

Ivermectin: Difficulties in resolving pharmacokinetic and pharmacodynamic relationships in onchocerciasis
by: E N Shu, et al.
Published: (2004-01-01)

Importance of ivermectin to human onchocerciasis: past, present, and the future
by: Cupp EW, et al.
Published: (2011-05-01)

High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo.
by: Bethany Levick, et al.
Published: (2017-07-01)